Whitepaper: Handheld analyzers for the screening of pharmaceutical counterfeits
Posted: 1 October 2013 | Thermo Fisher Scientific
The magnitude of the counterfeit and substandard pharmaceutical problem has recently gained significant public attention due to a number of high profile incidents and greater media focus. The World Health Organization (WHO) estimates that up to 10% of the world’s drugs are substandard or counterfeit and are expected to reach $75B. Even more significantly, it is estimated that 700,000 lives will be lost each year due to counterfeit malaria and tuberculosis drugs alone (International Policy Network, 2009).
This whitepaper is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Whitepaper: Drug repurposing trends and strategic approaches for shortening timelines
- Implementing the FAIR data principles is now a critical endeavour
- The role of digital transformation in achieving Pharma 4.0
- How COVID-19 has accelerated digital transformation and how laboratory orchestration platforms are changing the landscape
- Enabling compliant data management with a comprehensive informatics solution